performance
Quality Rating
Buy PE-22-28 10mg
Spadin analogue — antidepressant and neurogenesis via TREK-1 channel modulation
TREK-1 blockadeRapid antidepressant onsetHippocampal neurogenesis
Who This Is For
Researchers studying novel antidepressant mechanisms, or users seeking rapid mood improvement without SSRI-type side effects.
Overview & Benefits
PE-22-28 targets the TREK-1 potassium channel — a mechanism completely distinct from SSRIs, SNRIs, or MAOIs. TREK-1 blockade produces rapid antidepressant effects (onset within days rather than 4–6 weeks) alongside hippocampal neurogenesis and neuroprotection. The parent compound Spadin was discovered as a natural TREK-1 blocker; PE-22-28 is a synthetic optimized analogue with improved potency and bioavailability.
Key Benefits
- Rapid antidepressant onset via TREK-1 blockade — days, not weeks
- Hippocampal neurogenesis alongside mood improvement
- Neuroprotective against oxidative and excitotoxic stress
- Non-serotonergic mechanism — no SSRI-type sexual dysfunction or withdrawal
- Novel target for treatment-resistant depression research
Protocols & Dosing
Research Protocol
Once daily subcutaneous5–25mcg subcutaneous
For laboratory research use only. Monitor mood and cognitive metrics.
Buy PE-22-28 10mg
$79.99
Buy Now — $79.99Buy at PhiogenResearch-grade · COA verified · Phiogen
Categoryperformance
Typeinjectable
Quality Rating★★★☆☆
VendorPhiogen
Also Needed
PE-22-28 10mg
$79.99